Ireland
--:--IST
Active, not recruiting Not applicable

Clinical and Radiographic Outcomes of Pulpotomy Versus Pulpectomy in Primary Molars With Symptomatic Irreversible Pulpitis

NCT07783217 · tracked via the Priya Life Science Egypt tracker
Phase
Not applicable
Started
2025-07-15
Last updated
2026-08-24

Condition(s) studied

Irreversible Pulpitis

Investigational drug(s) / intervention(s)

MTA pulp dressing materialMetapex →

MTA pulp dressing material: The patients with symptomatic irreversible pulpitis in their primary molars was treated by MTA pulpotomy

Metapex: The patients with symptomatic irreversible pulpitis in their primary molars was treated by Metapex pulpectomy

Study summary

The goal of this clinical trial is to learn if MTA pulpotomy compared to pulpectomy have the same clinical and radiographic success in treatment of primary molars diagnosed with symptomatic irreversible pulpitis.

The main questions it aims to answer are:

Does MTA pulpotomy compared to pulpectomy have the same clinical and radiographic success in treatment of primary molars diagnosed with symptomatic irreversible pulpitis?

Eligibility

Sex
ALL
Min age
4 Years
Max age
8 Years
Healthy volunteers
No
Inclusion Criteria: * healthy and cooperative children * primary mandibular second molars with deep carious lesions and vital pulp * restorable crowns * history of spontaneous persistent lingering pain * normal radiographic appearance Exclusion Criteria: * clinical signs and symptoms of pulp necrosis * radiographic evidence of pathological root resorption

Primary outcome measure(s)

  • proportion of treated teeth demonstrating clinical and functional success during follow up intervals — at 3-month postoperatively, at 6-month postoperatively, at 12-month postoperatively, at 18-month postoperatively
    score 0 was applied for non functional teeth and score 1 was applied for functional teeth

Trial sites (1)

FacilityCityRegionStatus
Minia University Dental Hospita Minya Egypt
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07783217 on ClinicalTrials.gov ↗ ← All trials in Egypt